PITTSBURGH, Oct. 28, 2016 /PRNewswire/ -- Cognition Therapeutics, Inc., a clinical stage neuroscience therapeutics company, announced today that Kenneth I. Moch has been appointed President and Chief Executive Officer of the company. Mr. Moch will also join the company's Board of Directors.
Mr. Moch brings to Cognition more than 25 years of experience in creating, managing and financing biomedical companies. Over the course of his career, he has led the development of five life science companies, having previously served as President and CEO of Chimerix Inc., Alteon Inc., Biomedical Enterprises and Biocyte Corporation. Mr. Moch was also co-founder and Vice President of The Liposome Company, Inc.
Prior to joining Cognition, Mr. Moch has been a Managing Partner of The Salutramed Group, a strategy consulting firm. He has also been a Managing Director, Healthcare Banking at ThinkEquity Partners and a management consultant with McKinsey & Company, Inc. Mr. Moch holds an A.B. degree in biochemistry from Princeton University and an MBA from the Stanford Graduate School of Business.
"I am honored to assume this responsibility as Cognition Therapeutics progresses CT1812, its lead first-in-class compound, through Phase 1 clinical testing and into Phase 2 testing in Alzheimer's disease," said Mr. Moch. "This is the right time to accelerate Cognition's development and partnering activities. I look forward to working with the outstanding scientific and clinical development team, including founder and CSO Susan Catalano, PhD, to advance CT1812 in the clinic alone and in conjunction with future partners."
"We are truly delighted to have Ken bring to Cognition his extensive experience leading and financing both public and private biotechnology companies," said Robert Gailus of Ogden CAP, acting chairman of the Cognition Board of Directors. "Ken will play a pivotal role in advancing Cognition's mission as the company matures to focus on the clinical development of CT1812."
"We are thrilled by the addition of Ken to the management team," said Dr. Catalano. "His invaluable experience will allow us to expedite the development of our clinical candidates, particularly CT1812, and expand our pipeline of novel therapeutics. We look forward to leveraging our scientific expertise to further capitalize on the potential of Cognition's discovery platforms."
Mr. Moch succeeds Hank Safferstein, JD, PhD, who will remain with Cognition in an executive leadership capacity. "Hank has made tremendous contributions to Cognition over the past eight years, and I look forward to working with him as we build Cognition and focus on helping the millions of individuals in need," said Mr. Moch.
About Cognition Therapeutics, Inc.
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer's disease and potentially other neurocognitive disorders. CogRx's lead clinical stage drug candidate, CT1812, currently in Phase 1 clinical testing, has shown the ability to restore memory to normal in Alzheimer's disease models. Additional information about Cognition, CT1812 and the company's drug development programs may be found online at http://www.cogrx.com.
SOURCE Cognition Therapeutics, Inc. (CogRx)